Business Context and Reporting Period
Company: Galectin Therapeutics Inc. (GALT)
Filing Type: Form 8-K (Current Report)
Date of Report: November 10, 2025
Event: Regulation FD Disclosure regarding the presentation of NAVIGATE trial results at the American Association for the Study of Liver Diseases (AASLD) 2025 Annual Meeting.
Key Financial Metrics
This filing is a current report regarding a clinical trial update and does not contain financial statements. The text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
No financial material changes are reported in this document. The primary material event is the dissemination of clinical data from the NAVIGATE trial, which is detailed in the press release and corporate presentation furnished as Exhibits 99.1 and 99.2.
Guidance, Outlook, and Risks
Management Commentary: The Company issued a press release and updated its Corporate Presentation to share NAVIGATE trial results.
Forward-Looking Statements: The filing contains forward-looking statements based on current expectations. These are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially.
Legal Status of Information: Information furnished under Item 7.01 and the associated exhibits is deemed "furnished" and not "filed" for purposes of Section 18 of the Exchange Act, limiting liability and incorporation by reference.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific details on the NAVIGATE trial results.
- Examine Exhibit 99.2 (Corporate Presentation) for updated clinical timelines and strategic outlook.
- Verify the specific limitations and risk factors associated with the forward-looking statements referenced in the exhibits.
- Check subsequent filings for any financial impact resulting from the trial outcomes.